Yvette
Yvette Fleury Rey, Ursy CH
Patent application number | Description | Published |
---|---|---|
20100196536 | NATURAL TASTE ENHANCING SAVOURY BASE AND A PROCESS FOR ITS PREPARATION - The invention concerns a cultured savoury base with increased umami power comprising: up to 80% of naturally derived compounds taken in the group consisting of glutamate, IMP and GMP, naturally food derived compounds such as organic acids, amino acids, peptides and aroma compounds. | 08-05-2010 |
20100233330 | BAKED COMPOSITION - The present invention relates to a baked foodstuff with an improved flavour and an improved texture. Also to compositions for generating these improved flavours and textures in baked foodstuffs which compositions comprise non pre-reacted flavour precursors which react on heating to generate the flavours. | 09-16-2010 |
20120315354 | NATURAL TASTE ENHANCING SAVOURY BASE AND A PROCESS FOR ITS PREPARATION - The present invention concerns a taste enhancing savoury base comprising:—between 8 to 80% of naturally derived compounds taken in the group consisting of glutamate, IMP and GMP,—naturally food derived compounds such as organic acids and their salts, amino acids, peptides and aroma compounds, wherein said base is obtained through a prokaryotic fermentation with a bacteria taken from the group consisting of | 12-13-2012 |
Yvette Mettey, Vincennes FR
Patent application number | Description | Published |
---|---|---|
20090048260 | Use of pyrrolopyrazine derivatives for the production of medicaments for the treatment of mucoviscidosis and diseases related to protein addressing errors in cells - The invention relates to the use of pyrrolopyrazine derivatives for the treatment of mucoviscidosis and diseases related to protein addressing errors in cells, said derivatives being of formula (I): where R2 and R3 independently=H, C1-C6 straight or branched chain optionally-substituted alkyl, R6=an aromatic ring Ar or cycloalkyl, optionally substituted, said cycloalkyl optionally substituted by an aryl group which may equally be substituted, R7=H, C1-C6 alkyl, (alk.) | 02-19-2009 |
Yvette Mettey, Poitiers FR
Patent application number | Description | Published |
---|---|---|
20110092483 | SCREENING MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND SCREENED MOLECULES - A kit and a method for identifying compounds having anti-prion activity are provided. The kit comprises a yeast of phenotype [PSI+]; an antibiogram; and a prion curing agent in a sub-effective dose, wherein the yeast has the adel-14 allele of the ADE1 gene and an inactivated ERG6 gene. Compounds and pharmaceutical compositions having anti-prion activity are also provided, which are useful for treating various neurodegenerative diseases, including polyglutamines expansion associated diseases; Huntington's disease; Kennedy disease; amyotrophic lateral sclerosis; cerebellous autosomic ataxies; dentalorubral-pallidoluysian atrophy; and spino-bulbar amyotrophy. | 04-21-2011 |
20120122916 | SCREENING MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND SCREENED MOLECULES - The invention concerns screening molecules with anti-prion activity. More particularly, it concerns kits for screening molecules with anti-prion activity characterized in that they comprise in combination a [PSI+], phenotype yeast, an antibiogram and an agent for purifying prions at sub-efficient doses, said yeast including the ade1-14 allele of the ADE1 gene and an inactivated ERG6 gene, the screening methods, and a family of molecules with anti-prion activity isolated by the inventive screen. The invention is applicable to anti-prion agents for producing medicines in particular for treating neurodegenerative diseases involving protein aggregates. | 05-17-2012 |
Yvette Muneaux, Les Matelles FR
Patent application number | Description | Published |
---|---|---|
20080214538 | Pyridoindolone Derivatives Substituted in the 3-Position by a Phenyl, Their Preparation and Their Application in Therapeutics - The present disclosure relates to pyridoindolone derivatives of general formula (I): | 09-04-2008 |
20080262020 | 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof - The disclosure relates to compounds of formula (I): | 10-23-2008 |
20090042924 | Pyridoindolone Derivatives Substituted in the 3-position by a Heterocyclic Group, Their Preparation and Their Application in Therapeutics - The present disclosure relates to pyridoindolone derivatives of general formula (I): | 02-12-2009 |
Yvette Speziani, Miami, FL US
Patent application number | Description | Published |
---|---|---|
20100006461 | PLANT PRODUCT, COMPONENTS THEREFOR AND METHODS RELATING THERETO - A plant product includes a plant item and an envelope attached directly to the plant item wherein a flat object, such as a flattened vase, an instruction card, a storybook, a seed packet or a greeting card, is disposed in the envelope's interior. The plant item may be wrapped in a wrapper to which the envelope is secured, such as by an adhesive. Also disclosed is a structure for an exemplary envelope and flattened vase combination. A method utilizing these articles is also described. Where a flattened vase is used, it is of a type that can be selectively configured to an expanded state to receive the plant item. | 01-14-2010 |
Yvette Stallwood, Suffolk GB
Patent application number | Description | Published |
---|---|---|
20120148568 | Variant Immunoglobulins with Improved Manufacturability - This invention relates to the modification of the amino acid sequence of an immunoglobulin molecule at certain key positions within regions of the VH and VL FR and CDR3 domains and/or the CH1 domain which are prone to aggregation. Immunoglobulins modified as described may display improved manufacturability, for example, reduced aggregation propensity and/or increased production levels. | 06-14-2012 |
Yvette Stallwood, Cambridge GB
Patent application number | Description | Published |
---|---|---|
20090286745 | INHIBITION OF ALPHA-SYNUCLEIN AGGREGATION - This invention relates to the inhibition of alpha-synuclein aggregation using peptidyl compounds which are retroenantiomers of the alpha-synuclein sequence, in particular retroenantiomers of sequences in the regions between residues 1 to 60 or residues 61 to 96. Peptidyl compounds of the invention may optionally be coupled to doperminergic targeting moieties and/or blood brain barrier transport moieties and may be useful in the treatment of alpha-synucleinopathies such as Parkinson's disease. | 11-19-2009 |
Yvette Van Kooyk, Amsterdam NL
Patent application number | Description | Published |
---|---|---|
20100028418 | GAINAC SPECIFIC BINDING MOLECULES AND USES THEREOF - The present invention provides among others means and methods for detecting terminal GalNAc containing molecules. A preferred molecule for detecting said structures is a molecule comprising a carbohydrate binding part of MGL. | 02-04-2010 |
20120251557 | GalNAc-SPECIFIC BINDING MOLECULES AND USES THEREOF - The present invention provides, among others, means and methods for detecting terminal GalNAc-containing molecules. A preferred molecule for detecting the structures is a molecule comprising a carbohydrate binding part of MGL. | 10-04-2012 |
20140072593 | METHOD FOR SUPPRESSING AN IMMUNE RESPONSE - The invention is in the field of molecular immunology, more in particular in the field of medical treatment of animals such as humans suffering from unwanted immune reactions. The invention relates to methods for the treatment of unwanted immune reactions and provides means and methods for suppressing an immune response. The present invention relates in particular to regulatory T cells and methods of long-term, culture-expanding, activating and using same in immunotherapy and for the suppression of autoimmune responses, allergies and inflammatory diseases. The invention provides a sia alpha 2,3-conjugated antigen for use in the suppression of an immune response in a patient in need of such a treatment. | 03-13-2014 |